FDA Approved: TAGRISSO — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approves a supplemental application for Tagrisso (osimertinib) submitted by AstraZeneca, resulting in updated labeling and/or an expanded approved use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

SUPPL AP for TAGRISSO (OSIMERTINIB)